GDRX logo

GOODRX HOLDINGS INC-CLASS A

GDRXNASDAQ
๐Ÿ† #2012 by market capEarnings Nov 3US Equity
$3.65โ–ผ $0.14 (โˆ’3.95%)
Live
1hโ–ผ 0.8%
24hโ–ผ 4.0%
7dโ–ฒ 11.6%
14dโ–ฒ 13.4%
30dโ–ฒ 20.1%
1yโ–ฒ 4.6%
๐ŸฆMarket Cap
$1.24B
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
-1.8%
Declining
๐Ÿ“ŠGross Margin
90.8%
High
๐Ÿ’ตFCF Margin
18.0%
Healthy
โš–๏ธP/S Ratio
1.6x
Cheap
Otter Score
46
Weak

Trading Snapshot

Day Range
$3.61 โ€“ $3.67
52-Week Range
$1.77 โ€“ $5.81
Volume
$3.46B
Avg Volume
$2.70B
Shares Outstanding
338.7M
Next Earnings
Sep 20, 2026

Fundamentals Snapshot

Annual Revenue
$797M
Last Q Revenue
$200M
P/E Ratio
76.8
P/S Ratio
1.6x
EPS (TTM)
$0.05
Dividend Yield
โ€”

Why Investors Own GDRX

  • โœ“High-growth profile โ€” revenue up +24.3% YoY with expanding US Equity exposure.
  • โœ“Healthy economics โ€” 59% gross margin and 24% free-cash-flow margin.
  • โœ“New products and segments could unlock additional revenue streams.
โš ๏ธ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$797Mโ–ฒ +24.2% YoY
Gross Margin (TTM)
58.5%โ–ผ โˆ’0.1% YoY
Operating Income (TTM)
$168Mโ–ฒ +24.2% YoY
Free Cash Flow (TTM)
$187Mโ–ฒ +24.2% YoY

About GOODRX HOLDINGS INC-CLASS A

GoodRx Holdings, Inc. provides American consumers with essential resources and tools to compare and ultimately lower the cost of their prescription medications. The company operates a digital platform dedicated to price comparison, delivering customized, geographically tailored prescription pricing. It also grants access to special, negotiated rates through unique GoodRx codes, which can be utilized for savings on prescriptions throughout the entire United States. Beyond this core offering, the firm also extends its portfolio to include subscription services, programs designed for pharmaceutical manufacturers, and telehealth capabilities. GoodRx additionally collaborates with pharmacy benefit managers, entities responsible for managing drug formularies and overseeing prescription transactions, including the critical task of setting prices between consumers and pharmacies. The company was founded in 2015 and maintains its principal office in Santa Monica, California.

๐Ÿฆฆ

Otter Score Breakdown

โ“˜
๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
โšกMomentumโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Weak
46/100

Analyst Ratings

โ“˜
Consensus
Buy
21 analysts
Strong Buy4
Buy6
Hold9
Sell2
Strong Sell0
Ratings as of Aug 2026

Latest News & Updates

SeekingAlphaยท8h ago

GoodRx: Direct Brand Launches And New Subscription Plans Are Offering Hope

GoodRx rebounds from $2.50 with improved traction and new offerings, but valuation and risk stay balanced. Click here to read an analysis of GDRX stock now.

๐Ÿ›ฐ๏ธ
Benzingaยท1d ago

TD Cowen Maintains Buy on GoodRx Holdings, Raises Price Target to $5

TD Cowen analyst Charles Rhyee maintains GoodRx Holdings (NASDAQ:GDRX) with a Buy and raises the price target from $4 to $5.

SeekingAlphaยท5d ago

GoodRx Holdings, Inc. (GDRX) Q2 2026 Earnings Call Transcript

GoodRx Holdings, Inc. (GDRX) Q2 2026 Earnings Call August 6, 2026 8:00 AM EDTCompany ParticipantsAubrey Reynolds - Director of Investor RelationsWendy...

ChartMillยท6d ago

GoodRx (NASDAQ:GDRX) Q2 2026: Subscription and Pharma Direct Growth Lift Shares Despite Revenue Decline

GoodRx Q2 results beat estimates; shares rise 4% as subscription and Pharma Direct revenue surge, offsetting core prescription decline.

๐Ÿ›ฐ๏ธ
Benzingaยท6d ago

GoodRx Holdings Raises FY2026 Sales Guidance from $765.000M-$785.000M to $790.000M-$805.000M vs $775.751M Est

GoodRx Holdings (NASDAQ:GDRX) raises FY2026 sales outlook from $765.000 million-$785.000 million to $790.000 million-$805.000 million vs $775.751 million estimate.

๐ŸŒŒ
Benzingaยท6d ago

GoodRx Holdings Q2 Adj. EPS $0.08, Inline, Sales $200.411M Beat $193.162M Estimate

GoodRx Holdings (NASDAQ:GDRX) reported quarterly earnings of $0.08 per share which met the analyst consensus estimate. This is a 11.11 percent decrease over earnings of $0.09 per share from the same period last year.